We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Compendia Collaborates with MDS Pharma Services to Deliver Oncology Drug Development Solution
News

Compendia Collaborates with MDS Pharma Services to Deliver Oncology Drug Development Solution

Compendia Collaborates with MDS Pharma Services to Deliver Oncology Drug Development Solution
News

Compendia Collaborates with MDS Pharma Services to Deliver Oncology Drug Development Solution

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Compendia Collaborates with MDS Pharma Services to Deliver Oncology Drug Development Solution"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Compendia Bioscience has announced a strategic collaboration with MDS Pharma Services to deliver OncoPredictor, a novel solution for improved cancer drug development.

OncoPredictor combines MDS Pharma Services OncoPanel with Compendia Bioscience’s Oncomine’ for a solution that will provide guidance on patient groups most likely to respond to a new cancer therapy.

MDS Pharma Services OncoPanel service provides high content screening of up to 240 cancer cell lines to assess the cytotoxicity and chemotherapeutic potential of specific cancer drugs and drug combinations.

Compendia’s Oncomine, a database of cancer genomic profiles coupled with an analysis web application, provides genomic characterization and comparison of cancer cell lines to 2,000 disease signatures from more than 27,000 reference patients based on molecular, pathological and histological sub-types.

Through this collaboration, the OncoPredictor system will enable the analysis of drug sensitivity and resistance of novel drugs and drug combinations as well as the identification of associations with both disease sub-types and underlying tumor biology.

The solution will be delivered as a stand-alone, end-to-end service and will not require a license to any of Compendia’s Oncomine offerings.
Advertisement